


## Wednesday, November 14, 2018

MDCSCO
MARYLAND/DISTRICT OF COLUMBIA SOCIETY OF CLINICAL ONCOLOGY

## hosted Reception and Dinner - 6:30 p.m.

## Program

## 7:30 p.m. - 8:30 p.m.

## Baltimore Marriott Inner Harbor at Camden Yards

## Baltimore, MD

## PROGRAM DESCRIPTION

The high cost of oncology care remains a valid concern, particularly with the advent of increasingly expensive biologics and new payment models geared toward value-based care. One partial solution is the adoption of biosimilars into daily practice to limit patient costs. However, this requires a high level of expertise regarding the potential risks, benefits, and challenges associated with emerging agents that are similar – but not identical – to their reference products.

*The Transition from Biologics to Biosimilars in Oncology Treatment Paradigms: A Means to Reduce Healthcare Costs with Continued Effective Management of Patients* will use case-based examples to help clinicians appropriately analyze costs vs benefits in relation to fiscal concerns and patient outcomes while integrating biosimilars into daily practice.

## TARGET AUDIENCE

This activity is intended for medical oncologists, hematologists, nurses, pharmacists, and other clinicians involved in the care of patients with cancer.

## EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

*At the conclusion of this activity, participants should be able to demonstrate the ability to:*

- Analyze the clinical characteristics, including risks and benefits, of biosimilars and the associated clinical implications of expanded cancer treatment options in comparison to reference products/drugs
- Examine potential regulatory and clinical concerns of both healthcare providers and patients related to the incorporation of biosimilar agents into commonly used cancer treatment regimens
- Assess the implications of the high costs of biologic agents on cancer treatment and healthcare delivery in the US and worldwide

## ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

## CREDIT DESIGNATION

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: contact@potomacme.org.

## SPECIAL SERVICES

Event staff will be glad to assist you with any special needs.

## FEE AND RECEIVING CME CREDIT

There is no fee for this educational activity. To receive CME credit the participant must:

- Participate in this one-hour-long program in its entirety;
- Complete the evaluation form; and
- Return the evaluation form to logistics staff.

# DISCLOSURE STATEMENT

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

## STEERING COMMITTEE AND PROGRAM FACULTY

The steering committee and faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Gary H. Lyman, MD, MPH, FASCO, FRCP, FACP: *Research:* Amgen

Gary I. Cohen, MD, FACP, FASCO: *Stock/Shareholder*: AbbVie, Celgene, Exelixis, Nymox

Jeffery Crawford, MD: *Consultant/Independent Contractor:* Amgen, Enzychem, Merck, Pfizer; *Research:* Amgen, AstraZeneca, Bayer; *Chair/DSMB Member:* Celgene, G1 Therapeutics, Janssen, Merrimack, Mylan, Roche

## NON-FACULTY CONTENT CONTRIBUTORS

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Shawna Graves, PhD; Blair St. Amand; Lindsay Scott, PT, DPT, ATC: Nothing to disclose

# FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Jointly provided by the Potomac Center for Medical Education and Rockpointe Oncology

This activity has been supported through an educational grant from Pfizer.

# PROGRAM FACULTY / STEERING COMMITTEE

Gary I. Cohen, MD, FACP, FASCO
Director Emeritus, Sandra and Malcolm Berman Cancer Institute
Greater Baltimore Medical Center
Associate Professor
Johns Hopkins Oncology
Baltimore, MD

Gary I. Cohen, MD, FACP, FASCO is Director Emeritus of the Sandra and Malcolm Berman Cancer Institute at Greater Baltimore Medical Center (GBMC). He completed his undergraduate training at Duke University and graduated medical school at the University of Maryland. He subsequently completed his fellowship training in medical oncology at the Dana Farber Cancer Institute of Harvard University. During that time, he also completed a fellowship in hematology.

He currently holds an appointment as Associate Professor in the Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and is board-certified in internal medicine, medical oncology, and hematology. He is a Fellow of the American Society of Clinical Oncology and the American College of Physicians. Dr. Cohen established the Cancer Center at GBMC after being appointed Director in 1990. The center has been listed by *US News and World Report* as one of the top 50 cancer programs in the US.

He has co-authored numerous articles in the medical literature on various aspects of clinical cancer research. Dr. Cohen has been an active participant in the ECOG-ACRIN national cooperative clinical trials group, chairs the Community Scientific Committee, serves as Community Co-chair of the Melanoma Committee, and sits on the ECOG-ACRIN Executive Council. He is a Founder and Board Member of Gilchrist Hospice Care in Baltimore. He has served on many committees and boards for health-related organizations, including the Board of Directors of American Society of Clinical Oncology (ASCO) and Chair of the ASCO Measures Task Force (Quality Care Committee).

He served for 20 years as Administrative Director of the Sidney Kimmel Foundation for Cancer Research, which awarded more than $3 million dollars per year to outstanding young cancer scientists. He has won housestaff teaching awards on several occasions and has regularly been listed in local (*Baltimore Magazine*) and national physician surveys as a "Best Doctor" in Oncology.